Aktis Oncology, Inc. filings document the company’s transition into a Nasdaq-listed public oncology issuer and its disclosure obligations as a clinical-stage oncology company. S-1/A registration materials and current reports describe its targeted radiopharmaceutical pipeline, including AKY-1189 and AKY-2519, the miniprotein radioconjugate platform, collaboration revenue, and operating results.
Its filings also cover post-IPO governance and capital-structure matters, including amended charter provisions, authorized common, Class A common and undesignated preferred stock, classified board provisions, director appointments, board committee structure, financial-results exhibits, and registered common stock under the AKTS symbol.
Aktis Oncology, Inc. Schedule 13G shows Blue Owl Capital Holdings LP reports beneficial ownership of 3,161,348 shares of common stock, representing 5.92% of the class. The percentage is calculated from March 10, 2026 outstanding shares of 53,403,173, as disclosed in the issuer's 10-K.
Aktis Oncology reported its first quarterly results as a public company, showing higher collaboration revenue and a much stronger balance sheet after its IPO. Collaboration revenue from its Eli Lilly partnership grew to $3.2 million for the three months ended March 31, 2026, up from $1.4 million a year earlier. Operating expenses rose to $25.9 million, driven mainly by increased R&D spending on lead radiopharmaceutical candidates [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519 and higher public-company G&A costs, resulting in a net loss of $18.3 million versus $15.0 million in 2025. The January 2026 IPO and preferred share conversion transformed the capital structure, leaving Aktis with $538.5 million in cash, cash equivalents and marketable securities and total stockholders’ equity of $506.1 million. Management believes this cash runway will fund operations into 2029 as the company advances its miniprotein radioconjugate platform and clinical programs.
Aktis Oncology reported first quarter 2026 results alongside significant clinical and financing progress. Cash, cash equivalents and marketable securities were $538.5 million as of March 31, 2026, up from $226.8 million at year-end, helped by a January IPO of 20,297,500 shares at $18.00 per share for gross proceeds of about $365.4 million. The company expects this cash to fund operations into 2029.
Collaboration revenue rose to $3.2 million from $1.4 million, while research and development expenses increased to $20.0 million and general and administrative expenses to $5.9 million, leading to a net loss of $18.3 million versus $15.0 million a year earlier. Aktis highlighted Fast Track–designated AKY-1189 and B7-H3–targeting AKY-2519, with multiple Phase 1b trials underway or planned and initial data readouts expected in 2027.
Aktis Oncology director Glenn Gormley received a grant of 37,866 stock options to buy common stock at an exercise price of $18.09 per share. The options expire on April 15, 2036. According to the vesting terms, one-third vests on April 15, 2027 and the remaining shares vest in equal annual installments thereafter, subject to his continuous service through each vesting date.
Aktis Oncology, Inc. director Glenn Gormley filed an initial ownership report on Form 3 for the company’s common stock. The filing lists him as a director but does not report any specific share or derivative holdings at this time and shows no buy or sell transactions.
Aktis Oncology appointed Glenn Gormley, MD, PhD, age 72, as an independent Class I director, effective April 15, 2026, with a term running until the 2027 annual stockholder meeting. He will also serve as Co-Chairperson of the newly created Science and Technology Committee.
Under the company’s Non-Employee Director Compensation Policy, Dr. Gormley will receive annual cash fees of $45,000 for Board service and $15,000 for his committee co-chair role, both prorated. He was granted an option to purchase 37,866 shares of common stock under the 2026 Equity Incentive Plan, vesting in equal annual installments over three years, subject to continued service.
The filing also notes that current directors Helen S. Kim and Oleg Nodelman have decided to resign from the Board and all committees, effective May 20, 2026, and that their decisions were not due to any disagreement with the company’s operations, policies, or practices.
Aktis Oncology reported 2025 results and highlighted major R&D and financing milestones. The FDA cleared Investigational New Drug applications for AKY-2519, enabling a Phase 1b trial in mid-2026, while lead program AKY-1189 continues enrolling in a Phase 1b study and received Fast Track designation in February 2026.
Cash, cash equivalents and marketable securities were $226.8 million as of December 31, 2025, with a pro forma as adjusted cash position of $562.1 million after the January 2026 IPO, which the company believes will fund operations into 2029. 2025 collaboration revenue was $6.5 million, R&D expenses were $67.5 million, G&A expenses were $13.7 million, and net loss was $63.7 million, all higher than 2024 as the pipeline and organization expanded.
Aktis Oncology is a clinical-stage company developing targeted radiopharmaceuticals built on a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes precisely to solid tumors while clearing quickly from normal tissue.
Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4–expressing tumors, including urothelial cancer, breast and lung cancers. A Phase 1b trial is under way in the United States, with preliminary dose-escalation data expected in the first quarter of 2027, and the program has FDA Fast Track Designation for locally advanced or metastatic urothelial cancer after prior systemic therapies.
The second program, [225Ac]Ac-AKY-2519, targets B7-H3–expressing tumors such as prostate and lung cancers and is moving into a Phase 1b trial after FDA clearance of related INDs. Aktis is also building an internal cGMP radiopharmaceutical facility anticipated to be operational in the second half of 2026 and has a discovery collaboration with Eli Lilly that included a $60.0 million upfront payment and eligibility for up to $1.2 billion in milestones, while retaining full rights to its own pipeline. The company highlights substantial scientific, clinical, regulatory, funding and manufacturing risks typical for an early-stage oncology platform with no approved products.